🔎 Trials Near Me

홈 › 비소세포폐암 › 텍사스

텍사스의 비소세포폐암 임상 시험

비소세포폐암 관련 연구 213개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.

텍사스의 도시

공식 연구 텍스트(영어)

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Oncology Consultants PA, Houston
  • University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT05920356

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

  • Next Oncology - Austin, Austin
  • Next Oncology - Houston, Houston
  • Next Oncology - Dallas, Irving
  • 외 1개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07488676

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

  • START Fort Worth, Fort Worth
  • MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07659782

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  • University of Texas M. D. Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07111520

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  • University of Texas MD Anderson Cancer Center, Houston
  • Local Institution - 0173, San Antonio
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07100080

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • The University of Texas, MD Anderson Cancer Center - Woodlands, Conroe
  • Renovatio Clinical - El Paso, El Paso
  • The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
  • 외 10개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06758401

BostonGene and Exigent Genomic INsight Study

  • Oncology Consultants, Houston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06272864

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Hendrick Medical Center, Abilene
  • Houston Methodist San Jacinto Hospital, Baytown
  • Parkland Memorial Hospital, Dallas
  • 외 7개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04267848

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

  • MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07133425

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • NEXT Austin, Austin
  • START Center for Clinical Research, Fort Worth
  • University of Texas MD Anderson Cancer Center, Houston
  • 외 2개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06270706

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  • Oncology Consultants P.A. ( Site 0113), Houston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06345729

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

  • Mary Crowley Cancer Research Center, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04886804

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  • NEXT Dallas - Oncology Department, Irving
  • START | San Antonio, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06914128

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  • MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07020221

A Study of DS-3939a in Participants With Solid Tumors

  • The University of Texas Md Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07739966

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT04557449

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

  • TxO Central/South, Texas Oncology -Central/South Texas, Austin
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06868485

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  • NEXT Texas LLC - Austin, Austin
  • START Dallas Fort Worth, LLC, Fort Worth
  • MD Anderson, Houston
  • 외 4개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07503808

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  • Texas Oncology, Beaumont
  • Texas Oncology - DFW, Dallas
  • Texas Oncology - San Antonio, San Antonio
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07680790

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Austin
  • Research Site, Denton
  • Research Site, Plano
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07291037

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  • Old Parkland Hospital Hematology Oncology Clinic, Dallas
  • UT Southwestern Medical Center, Dallas
  • DHR Health Oncology Institute, Edinburg
  • 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06216301

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Texas Oncology - DFW ( Site 8103), Dallas
  • UT Southwestern Medical Center ( Site 0190), Dallas
  • Houston Methodist Cancer Center ( Site 0191), Houston
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06623422

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  • University of Texas-MD Anderson Cancer Center ( Site 3283), Houston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07513376

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Texas Oncology - West Texas, Abilene
  • University of Texas MD Anderson Cancer Center, Houston
  • Local Institution - 0517, Houston
  • 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06561386

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

  • Texas Oncology-Longview Cancer Center, Longview
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07566052

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
  • University of Texas at Tyler, Tyler
피험자 모집 중1상
18세 ~ 99세 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT06983743

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • The University of Texas Health Science Center at Tyler, Tyler
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT04198766

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Texas Oncology - West Texas, Abilene
  • Texas Oncology-Northeast Texas, Allen
  • Texas Oncology-West Texas, Amarillo
  • 외 61개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07144280

A 2-part Phase 1/2 Open-label Trial on ODM-212

  • START Dallas-Fort Worth, Fort Worth
  • NEXT Oncology, Irving
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07563738

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center - Conroe, Conroe
  • University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
  • 외 3개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07090499

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • The University of Texas Southwestern Medical Center at Dallas, Dallas
  • Renovatio Clinical - El Paso, El Paso
  • JPS Health Network, Fort Worth
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06793215

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

  • MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT05789082

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  • Texas Oncology - Amarillo Cancer Center, Amarillo
  • Texas Oncology-Austin Central, Austin
  • Texas Oncology, Denton
  • 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07361497

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University of Texas MD Anderson Cancer Center, Houston
  • South Texas Accelerated Research Therapeutics (START), San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06465069

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • The Center for Cancer and Blood Disorders, Fort Worth
  • Kelsey-Seybold Clinic, Houston
  • Houston Methodist Hospital, Houston
  • 외 4개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06890598

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  • The University of Texas - M.D. Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06706076

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Texas Oncology, Abilene
  • Texas Oncology - Central / South Texas, Austin
  • Mary Crowley Cancer Research, Dallas
  • 외 3개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05579366

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The University of Texas - MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06400472

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • The University of Texas MD Anderson Cancer Center (site 127), Houston
피험자 모집 중1/2상
18세 ~ 80세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT03556228

SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

  • Mary Crowley Cancer Research, Dallas
  • MD Anderson, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07857616

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.